…successfully commercialize UGN-102 and other products in development; the potential impact of COVID-19 on UroGen’s clinical trials, preclinical studies, supply chain and other business operations; and other factors discussed in the “Risk Factors” section of UroGen’s most recent Annual Report on Form 20-F filed with the Securities and Exchange Commission, as well as discussions of potential risks, uncertainties, and other important factors in UroGen’s subsequent filings with the Securities and Exchange Commission. In addition, any forward-looking statements represent UroGen’s views only as of the date of this press release and should not be relied upon as representing its views as of any subsequent date. UroGen explicitly disclaims any obligation to update any forward-looking statements.
Contacts
Investors:
SMP Communications
Susan Kim, 301-332-0517
[email protected]
Media:
Sloane & Company
Dan Zacchei / Joe Germani, 212-486-9500
[email protected] / [email protected]”